S

Stoke Therapeutics

Develops targeted gene upregulation therapies

Vice President - Regulatory Strategy and CMC

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • A Ph.D., Pharm.D., M.S., or advanced scientific degree in Pharmaceutical Sciences, Chemistry, Biochemistry, Chemical Engineering, Biotechnology, or a related discipline is preferred.
  • 12+ years of progressive experience in biotechnology, pharmaceutical, or cell and gene therapy industries, with at least 6 years in a leadership capacity.
  • Deep expertise in global Regulatory Affairs and CMC development.
  • Demonstrated success leading major regulatory submissions and health authority interactions.
  • Experience advancing products from early development through commercialization.
  • Significant experience managing multiple development programs.
  • Proven executive leadership experience building and managing multidisciplinary teams.
  • Executive presence and ELT-level communication.
  • Risk assessment and decision-making.
  • Cross-functional influence and collaboration.
  • Change management and organizational leadership.
  • Negotiation and stakeholder management.
  • Financial and operational planning.

Responsibilities

  • Provide oversight and guidance into development and implementation of integrated global regulatory strategies for Stoke programs.
  • Lead and manage teams responsible for INDs, CTAs, IMPDs, BLAs, NDAs, MAAs, and post-approval submissions.
  • Serve as the executive lead for interactions with FDA, EMA, MHRA, PMDA, Health Canada, and other global regulatory agencies.
  • Provide strategic regulatory guidance to executive leadership and program teams regarding development pathways, agency expectations, accelerated programs, and risk mitigation.
  • Monitor evolving regulatory requirements and assess impacts on development and commercial programs.
  • Support corporate business development, licensing, due diligence, and portfolio evaluation activities.
  • Provide oversight and guidance into enterprise-wide CMC strategies for drug substance, drug product, analytical development, process development, manufacturing, supply, and combination drug-device development.
  • Ensure phase-appropriate CMC development plans are aligned with regulatory expectations and business objectives.
  • Lead and manage teams responsible for CMC readiness activities supporting clinical studies, registration, launch, and lifecycle management.
  • Partner with Quality and Technical Operations to ensure compliance with cGMP, ICH, FDA, EMA, and global regulatory requirements.
  • Provide strategic regulatory guidance on long-range manufacturing and supply strategies to support global commercial expansion.
  • Build, mentor, and lead high-performing Regulatory Strategy and CMC teams.
  • Establish department goals, governance processes, resource planning, and budget management.
  • Foster a collaborative, science-driven, and compliance-focused culture.
  • Influence company strategy through participation on executive leadership committees and governance boards.
  • Manage external consultants, CROs, CDMOs, and strategic partnerships supporting regulatory and manufacturing activities.
  • Support launch readiness activities and commercial regulatory strategies.
  • Oversee post-approval changes, global lifecycle management activities, and market expansion initiatives.
  • Ensure regulatory compliance throughout the product lifecycle while enabling operational flexibility and business growth.
  • Identify regulatory and manufacturing risks and develop proactive mitigation strategies.

About the Company

Stoke Therapeutics

Develops targeted gene upregulation therapies

Stoke Therapeutics develops therapies for severe genetic diseases caused by loss of function in a single gene, aiming to restore missing proteins by upregulating protein expression. Its main product approach relies on the TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which delivers precise, durable, and controllable upregulation of gene expression across a range of tissues to re-create the missing protein. Compared with many biotech firms, Stoke centers on upregulating endogenous gene output rather than replacing genes or adding new ones, and focuses on disease-modifying treatments for rare disorders with unmet medical needs. Revenue comes from partnerships, licensing agreements, and, ultimately, commercialization of its therapies. The company’s goal is to provide targeted, durable treatments that address the underlying genetic deficiency and improve outcomes for patients with limited options.

Company size
201-500
Company stage
IPO
Headquarters
Bedford, TX
Founded
2014

Recently Posted Jobs

Explore more opportunities at Stoke Therapeutics

See more jobs